AC Immune (NASDAQ: ACIU) Updates Morphomer Tau License and Collaboration with Lilly

April 7, 2026

Key Developments AC Immune (NASDAQ: ACIU) announced a significant amendment to its Morphomer® Tau license and ongoing collaboration agreement with Eli Lilly and Company, enhancing their strategic partnership in neurodegenerative disease research. This amendment redefines key terms of their joint efforts targeting tauopathies, a group of disorders associated with abnormal tau protein accumulation, including Alzheimer’s disease. The revised agreement aims to accelerate the development and commercialization of novel therapeutics derived…

Read More >>